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rsit€atSeveral prognostic factors for the outcome after allogeneic hematopoietic stem-cell transplant (HSCT) from
matched unrelated donors have been postulated from registry data; however, data from randomized trials
are lacking.We present analyses on the effects of patient-related, donor-related, and treatment-related prog-
nostic factors on acute GVHD (aGVHD), chronic GVHD (cGVHD), relapse, nonrelapse mortality (NRM),
disease-free survival (DFS), and overall survival (OS) in a randomized, multicenter, open-label, phase III trial
comparing standard graft-versus-host-disease (GVHD) prophylaxis with and without pretransplantation
ATG-Fresenius (ATG-F) in 201 adult patients receiving myeloablative conditioning before HSCT from
HLA-A, HLA-B antigen, HLA-DRB1, HLA-DQB1 allele matched unrelated donors. High-resolution testing
(allele) of HLA-A, HLA-B, and HLA-C were obtained after study closure, and the impact of an HLA 10/10
4-digit mismatch on outcome and on the treatment effect of ATG-F versus control investigated. Advanced
disease was a negative factor for relapse, DFS, and OS. Donor age$40 adversely affected the risk of aGVHD
III-IV, extensive cGVHD, and OS. Younger donors are to be preferred in unrelated donor transplantation.
Advanced disease patients need special precautions to improve outcome. The degree of mismatch had no
major influence on the positive effect of ATG-F on the reduction of aGVHD and cGVHD.
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tablished in matched sibling donor transplantation [2];
however, application in the setting of unrelated donor
transplant results in less reliable outcome because of
the higher rates of GVHD and transplantation-
related mortality [3-5]. The practice of allogeneic
HSCT has changed over the years, eg, with the
improvement of HLA-matching increasing use of
less intensive conditioning and peripheral blood
(PB)-derived grafts as well as better supportive care
and routine introduction of quality management pro-
grams [6].
In order to reduce the risk of GVHD in transplanta-
tion from unrelated donors, various methods of in vivo
and in vitro T cell depletion have been tested without
showing a benefit [7,8]. Recently, we could demonstrate
in a randomized trial that the addition of antithymocyte
globulin Fresenius (ATG-F) to standard CyA/short
course methotrexate for GVHD prophylaxis results in
reduced incidence of acute GVHD (aGVHD) and
chronic GVHD (cGVHD) without an increase in
relapse or nonrelapse mortality (NRM), and without
compromising overall survival (OS) [9].
When choosing an unrelated donor, emphasis is
put on HLA-matching and many centers require a 10
of 10 allele (HLA-A, HLA-B, HLA-C, HLA-DRB1,
and HLA-DQB1) matched donor because mismatch-
ing in 1 or more loci results in increased GVHD and
worse outcome [10-14]. In our trial, donors and
recipients were required to be antigen matched for
HLA-A and HLA-B (2-digit) and allele matched for
HLA-DRB1 and HLA-DQB1 (4-digit). Matching
for HLA-C was not required. High-resolution testing
(4-digit allele) results of HLA-A, HLA-B, and HLA-C
were obtained retrospectively from all study centers
after study closure. In this article, we are able to pres-
ent, we believe for the first time, results on the impact
of an HLA 10/10 4-digit mismatch on outcome and on
the treatment effect of ATG-F versus control.
Analyses of phase II or registry data suggest that ad-
ditional other factors affect outcome after unrelated do-
nor transplantation [15-21]. Because of the retrospective
natureof thesedata, thedefinite valueof each factor isnot
clear for the general practice in allogeneic HSCT from
unrelated donors. A randomized trial is an ideal study
design for a reliable analysis of the effects of prognostic
factors on outcome. Treatment is standardized and
because of the randomized allocation it is independent
from prognostic factors and, thus, is not to be regarded
as a confounding variable [22].
The focus of a recent analysis of our randomized
trial was cGVHD [23]. As one aspect, we looked at
the effects of prognostic factors on cGVHD.Our anal-
ysis showed that donor age of 40 years ormore and type
of disease diagnosis affected the risk of extensive
cGVHD, and that the type of disease diagnosis and
type of conditioning regimen affected the risk oflimited or extensive cGVHD. In this report, we present
a comprehensive analysis of the effects of prognostic
factors on aGVHD and cGVHD, relapse, NRM,
disease-free survival (DFS), and OS after an extended
follow-up of a median of 3 years of our randomized
GVHD prevention trial in unrelated donor transplan-
tation [9].PATIENTS AND METHODS
Patients and Procedures
As reported previously [9], within a randomized
prospective multicenter phase III trial, a standard
GVHD prophylaxis with the addition of ATG-F
(ATG-F group) was compared to a standard prophy-
laxis alone (control group) in patients with acute
myeloid leukemia (AML), acute lymphoid leukemia
(ALL), myelodysplastic syndrome (MDS), chronic
myeloid leukemia (CML), osteomyelofibrosis
(OMF), receiving myeloablative conditioning before
HSCT from matched unrelated donors (Table 1)
with respect to GVHD, engraftment, relapse, NRM,
DFS, OS, and safety. The primary endpoint for the
treatment comparison was the occurrence of severe
aGVHD grade III to IV or death within 100 days
posttransplantation.
Standard GVHD prophylaxis was CyA starting
day 21 and a short course of methotrexate 15
mg/m2, day 11, and 10 mg/m2 days 13, 16, 111.
Patients in the ATG-F group received additional
ATG-F at a dose of 20 mg/kg on day 23, day 22,
and day 21 (total dose, 60 mg/kg) before transplanta-
tion. All patients received myeloablative conditioning
regimens (further details [9]).
Donors and recipients were required to be antigen
matched for HLA-A and HLA-B (2-digit) and allele
matched for HLA-DRB1 and HLA-DQB1 (4-digit).
Matching for HLA-C was not required. Since closure
of the trial, high-resolution testing (4-digit allele) results
of HLA-A, HLA-B, and HLA-C determined locally by
certified laboratories were obtained retrospectively
(Table 1).
Patients were recruited between May 2003 and
February 2007 in 33 European centers including
Israel. The study was approved by the appropriate
independent ethics committees, and was done in ac-
cordance with the good clinical practice guidelines,
the ethical principles of the Declaration of Helsinki,
the national law, and guidelines of the participating
countries. All patients gave written informed con-
sent. Project management, statistical planning and
analysis, randomization, data management, and clin-
ical monitoring were conducted by the Clinical Tri-
als Unit, University Medical Center Freiburg,
Germany, independently from the sponsor Fresenius
Biotech.
Table 1. Baseline Patient, Donor, and Treatment Character-
istics
Characteristic ATG-F (N 5 103) Control (N 5 98)
Patient age (median, range) 40 (18-60) 39 (18-60)
<40 years 47 50
$40 years 56 48
Donor age (median, range) 35 (20-58) 37 (18-56)
<40 years 62 64
$40 years 32 30
Unknown 9 4
Patient/donor sex
Patient male/donor female 14 13
Other 87 85
Unknown 2 0
Patient/donor CMV status
Patient negative/donor
negative
23 44
Other 80 54
Diagnosis
ALL 37 33
AML 55 46
CML 6 11
MDS 5 5
OMF 0 3
Disease status
Early 64 43
Advanced 39 55
Conditioning regimen
TBI/Cy 54 48
Busulfan/Cy 26 26
TBI/etoposide/Cy 11 6
TBI/other 7 9
No TBI/other 5 9
Stem-cell source
BM 21 16
PB 82 82
Number of infused CD34+ cells
(median, range)*
7.4 (0.1-28.5) 7.3 (2.4-17.1)
<7.5  106 cells/kg 43 41
$7.5  106 cells/kg 38 38
Unknown 1 3
Mean CyA level day 21 to day
+30 (median, range)
213 (115-449) 233 (114-437)
<220 ng/mL 53 42
$220 ng/mL 50 55
Unknown 0 1
HLA 10/10 mismatch (4-digit)
No mismatch 61 58
Mismatch 31 29
8/8† match, HLA-C
mismatch
18 16
8/8 mismatch,‡ HLA-C
mismatch
7 5
8/8 mismatch,‡ HLA-C
match
4 6
8/8 mismatch,‡ HLA-C
unknown
1 2
8/8 unknown, HLA-C
mismatch
1 0
Unknown 11 11
8/8 match, HLA-C
unknown
4 5
8/8 unknown 7 6
HLA 10/10 mismatch (4-digit)
No mismatch 61 58
Mismatch on HLA-class I
antigen, HLA-class II
allele level
23 24
HLA-A 2-digit mismatch 0 1
HLA-B 2-digit mismatch 0 1
HLA-C 2-digit mismatch 22 19
HLA-DQB1 4-digit
mismatch
1 2
(Continued )
Table 1. (Continued )
Characteristic ATG-F (N 5 103) Control (N 5 98)
HLA-DRB1 4-digit
mismatch
0 1
Mismatch on HLA-class
I allele level
8 5
HLA-A 4-digit mismatch 1 1
HLA-B 4-digit mismatch 2 2
HLA-C 4-digit mismatch 3 2
HLA-A and HLA-B 4-digit
mismatch
1 0
HLA-B and HLA-C 4-digit
mismatch
1 0
Unknown 11 11
HLA-C mismatch (2-digit/
4-digit)
No mismatch 67 65
Mismatch 26 21
2-digit match/4-digit
mismatch
4 2
2-digit mismatch 22 19
Unknown 10 12
ATG-F indicates antithymocyte globulin Fresenius; CMV, cytomegalovi-
rus; ALL, acute lymphoid leukemia; AML, acute myeloid leukemia; CML,
chronic myeloid leukemia; MDS, myelodysplastic syndrome; OMF, os-
teomyelofibrosis; TBI, total body irradiation; Cy, cyclosporin; BM,
bone marrow; PB, peripheral blood; CyA, cyclosporin A.
Data are n or median (range).
*Only for transplantation of PB (n 5 164).
†8/8 refers to HLA-A, HLA-B, HLA-DRB1, and HLA-DQB1.
‡Twenty-five patient/donor pairs with 8/8 mismatch: 6 had mismatch on
the HLA-A, HLA-B antigen, HLA-DRB1, HLA-DQB1 allele level, thus
being protocol deviations (1 ATG-F, 5 control); 19 had mismatch only
on the HLA-A, HLA-B allele level (11 ATG-F, 8 control, 2 HLA-A, 13
HLA-B, 4 HLA-A and HLA-B different).
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The effects of the following prognostic factors on
time to aGVHD grade II to IV, aGVHD III to IV,
time to limited/extensive cGVHD, extensive cGVHD,
time to relapse, time to NRM, DFS time, and OS time
were analyzed: patient age ($40 years versus\40 years),
donor age ($40 years versus\40 years), patient and do-
nor sex (patientmale/donor female versus other), patient
and donor cytomegalovirus (CMV) status (patient and
donor negative versus other), diagnosis (AML versus
MDS versus ALL versus CML/OMF), disease status
(advanced versus early), conditioning regimen (total
body irradiation [TBI] versus no TBI), stem cell source
(PB versus bone marrow [BM]), CD 341 cells infused
($7.5 versus\7.5  106 cells/kg in PB derived grafts
only), and CyA exposure (mean level $220 versus
\220 ng/mL during the initial 4 weeks posttransplanta-
tion). The endpoints were defined as described [9].
The probability of event over time in groups de-
fined by the prognostic factors was estimated by the
cumulative incidence function. Relapse and death
were considered as competing events for aGVHD
and cGVHD. Relapse and NRM were considered as
competing events, respectively. For patients who did
not experience the event in question, time from
Biol Blood Marrow Transplant 18:1716-1726, 2012 1719Prognostic Factors in Allogeneic HSCTtransplantation to the last documented follow-up was
used as a censored observation.
The prognostic effects of the factors with respect to
the time-to-event variables were analyzed with Cox re-
gressionmodels for the event-specific hazard functions
using 2-sided Wald tests. The randomized treatment
was included for adjustment. To estimate the effect
sizes, the hazard ratios (HRs) between groups defined
by the prognostic factors were calculated with 95%
confidence intervals (CIs). Univariate analyses of the
factors were performed, evaluating their effects sepa-
rately. In multiple regression analyses, those factors
that showed a prognostic effect in the univariate anal-
ysis with P # .05 were analyzed simultaneously.
For an investigation to determine if the effects of
the prognostic factors were influenced by the random-
ized treatment, Cox regression models were used, in-
cluding the prognostic factor, the treatment, and the
interactive effect between prognostic factor and treat-
ment. From these models, treatment-specific HRs be-
tween groups defined by the prognostic factors were
calculated with 95% CIs.
The influence of the degree of HLA-mismatch on
the time-to-event variables and on the treatment effect
(ATG-F versus control) was analyzed separately using
a Cox regression model including HLA-mismatch (4-
digit) 10/10, the treatment effect, the interaction be-
tween HLA-mismatch and treatment, disease status,
and stem-cell source. From this model, the treatment
effects (ATG-F versus control) were estimated sepa-
rately in patients with HLA 10/10 4-digit match, and
HLA 10/10 4-digit and tests for heterogeneous treat-
ment effects (interactions) were performed.
All analyses are post-hoc analyses of the random-
ized trial. No adjustment for multiple testing was per-
formed. Statistical analysis was performed using the
StatisticalAnalysis System, version 9.2.The study is reg-
istered with the World Health Organization primary
registers, numbers DRKS00000002/NCT00655343.RESULTS
Study Patients
Two hundred one adult patients with a median age
of 40 years (range, 18-60 years) were randomized to
ATG-F (n 5 103) or control (n 5 98) and underwent
transplantation. One further randomized patient did
not undergo transplantation and was excluded from
all analyses. Table 1 shows the baseline patient charac-
teristics indetail. Patients received as graft source either
BM (n 5 37) or granulocyte colony-stimulating factor
(G-CSF) stimulated PB apheresis products (n 5 164).
Median CD341 cell counts were 2.91  106/kg recip-
ient body weight and 7.39  106/kg recipient body
weight for marrow and PB grafts, respectively. Median
donor age was 36 years (range, 18-58 years).Since closure of the trial, high-resolution testing
(4-digit) results for HLA-A, HLA-B, HLA-DRB1,
and HLA-DQB1 (8/8) were obtained for 187 of the
201 study patient/donor pairs. Twenty-five of 187
pairs were mismatched (8/8) in HLA-A, HLA-B,
HLA-DRB1, and HLA-DQB1 (6 of them on the
HLA-A, HLA-B antigen, HLA-DRB1, and HLA-
DQB1 allele level, thus being protocol deviations,
and the other 19 on the HLA-A and HLA-B allele
level). Additionally, high-resolution testing (4-digit)
results, including HLA-C (10/10), were available for
179 patient/donor pairs. Thirty-four of 153 patient/
donor pairs with 8/8 match and available HLA-C test-
ing had HLA-Cmismatch (4-digit). Overall, 60 of 179
patient/donor pairs (34%) had a 4-digit difference. For
47 of them, the difference was on the HLA-class I an-
tigen, HLA-class II allele level; for 13 of them, the dif-
ference was on the HLA-class I allele level. Details are
given in Table 1.
The median follow-up time was 3 years (25% quar-
tile, 2.5 years; 75% quartile, 3.9 years). The aGVHD II
to IV and III to IV before relapse occurred in 83 and
36 patients, respectively, and limited/extensive and ex-
tensive cGVHDbefore relapseoccurred in 75 and47pa-
tients, respectively. Relapse was observed in 63 patients,
NRMwasobserved in52patients, resulting in115events
with respect to DFS. Overall, 103 patients have died.Effects of Prognostic Factors
The results of the univariate analyses of the effects
of prognostic factors are shown in Figure 1 and
Figure S1 (supplementary material) and Tables S1,
S2, S3, and S4 (supplementary material).
In univariate analyses, the following factors
showed effects with P # .05: patient age affected
aGVHD II to IV, NRM, and OS; diagnosis affected
aGVHD II to IV, aGVHD III to IV, limited/extensive
cGVHD, and extensive cGVHD; conditioning regi-
men affected limited/extensive cGVHD; disease status
affected aGVHD III to IV, relapse, NRM, DFS, and
OS; and donor age affected aGVHD III to IV, exten-
sive cGVHD, and OS.
These factors were included in multiple regression
analyses, in which the tests of the effects of the follow-
ing factors showed P # .05 (Table 2). Patients $40
years versus \40 years negatively affected NRM
(HR 5 1.81; 95% CI, 1.03-3.19; P 5 .041) and posi-
tively affected aGVHD II to IV (HR 5 0.62; 95%
CI, 0.40-0.97; P5 .034). There was no effect of patient
age on aGVHD III to IV, cGVHD, and on relapse. Di-
agnosis had an effect on aGVHD II to IV (P 5 .013),
on aGVHD III to IV (P 5 .036), on limited/extensive
cGVHD (P 5 .017), and on extensive cGVHD
(P 5 .032) with an increased risk for patients with
MDS and for patients with CML/OMF. Patients
with a TBI-containing conditioning regimen had
Figure 1. Effect of donor age, estimated from multiple regression model (Table 2). (A) Effect on acute graft-versus-host disease (aGVHD) III-IV, hazard
ratio ($40 versus\40 yr)5 2.57; 95% confidence interval (CI), 1.27-5.21; P5.009. (B) Effect on extensive chronic graft-versus-host disease (cGVHD),
hazard ratio ($40 versus\40 yr)5 2.06; 95% CI, 1.12-3.79; P5 .021. (C) Effect on overall survival, hazard ratio ($40 versus\40 yr)5 1.66; 95% CI,
1.10-2.51; P 5 .016.
1720 Biol Blood Marrow Transplant 18:1716-1726, 2012J. Finke et al.a decreased risk of limited/extensive cGVHD
(HR 5 0.39; 95% CI, 0.23-0.68; P 5 .0007). Condi-
tioning regimen had no effect on the other outcomes.
Advanced disease was a negative factor for relapse
(HR 5 1.72; 95% CI, 1.03-2.87; P 5 .038), DFS
(HR 5 1.74; 95% CI, 1.19-2.54; P 5 .004), and OS
(HR 5 1.94; 95% CI, 1.27-2.97; P 5 .002).Donor age$40 years adversely affected the risk of
aGVHD III to IV (HR 5 2.57; 95% CI, 1.27-5.21;
P 5 .009), extensive cGVHD (HR 5 2.06; 95% CI,
1.12-3.79; P 5 .021), and OS (HR 5 1.66; 95% CI,
1.10-2.51; P 5 .016). The cumulative incidents of
aGVHD III to IV and extensive cGVHD were 26%
and 35% for patients with donors of at least 40 years
Table 2. Effects of Prognostic Factors (Multiple Regression Analyses Adjusted for Treatment)
Factor Value
aGVHD II-IV aGVHD III-IV
HR 95% CI P Value HR 95% CI P Value
Patient age $40 versus <40 yr 0.62 0.40-0.97 .034 – – –
Donor age $40 versus <40 yr – – – 2.57 1.27-5.21 .009
Diagnosis MDS versus AML 3.09 1.28-7.45 .013 5.72 1.74-18.9 .036
ALL versus AML 1.28 0.77-2.11 1.19 0.52-2.73
CML/OMF versus AML 2.26 1.20-4.24 1.59 0.59-4.28
Disease status Advanced versus early – – – 2.11 0.95-4.69 .067
Factor Value
cGVHD Limited/Extensive cGVHD Extensive
HR 95% CI P Value HR 95% CI P Value
Donor age $40 versus <40 yr – – – 2.06 1.12-3.79 .021
Diagnosis MDS versus AML 1.95 0.79-4.81 .017 4.03 1.31-12.4 .032
ALL versus AML 1.60 0.88-2.89 1.59 0.77-3.25
CML/OMF versus AML 2.83 1.42-5.65 2.65 1.13-6.22
Conditioning regimen TBI versus no TBI 0.39 0.23-0.68 .0007
– – –
Factor Value
Relapse NRM
HR 95% CI P Value HR 95% CI P Value
Patient age $40 versus <40 yr – – – 1.81 1.03-3.19 .041
Disease status Advanced versus early 1.72 1.03-2.87 .038 1.69 0.95-2.99 .073
DFS OS
Factor Value HR 95% CI P Value HR 95% CI P Value
Patient age $40 versus <40 yr – – – 1.46 0.97-2.19 .070
Donor age $40 versus <40 yr – – – 1.66 1.10-2.51 .016
Disease status Advanced versus early 1.74 1.19-2.54 .004 1.94 1.27-2.97 .002
aGVHD indicates acute graft-versus-host-disease; HR, hazard ratio; CI, confidence interval; MDS, myelodysplastic syndrome; AML, acute myeloid leu-
kemia; ALL, acute lymphoid leukemia; CML, chronic myeloid leukemia; OMF, osteomyelofibrosis; cGVHD, chronic graft-versus-host-disease; TBI, total
body irradiation; NRM, nonrelapse mortality; DFS, disease-free survival; OS, overall survival.
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than 40 years, respectively. OS rates 3 years after
HSCT were 37% and 55% for patients with donors
of at least 40 years and \40 years, respectively.
When donor age was analyzed as a continuous
covariate, the risk of aGVHD III to IV and of extensive
cGVHD per donor age decade was increased
(HR 5 1.75; 95% CI, 1.18-2.58; P 5 .005 and
HR 5 1.38; 95% CI, 1.00-1.92; P 5 .051). The risk
of death per decade of donor age was increased
(HR 5 1.28; 95% CI, 1.01-1.61; P 5 .038).
Other analyzed factors such as patient and donor
sex, patient and donor CMV status, stem cell source,
CD 341 cell number infused (in PB-derived grafts
only), and CyA exposure during the initial 4 weeks
posttransplantation did not show significant effects in
our trial.
Interactions between Prognostic Factors and
Treatment
To examine whether the effects of prognostic fac-
tors were heterogeneous in the ATG-F group and the
control group, interactive effects between treatment
and prognostic factors were examined. Figure S2
(supplementarymaterial) shows the effects of the prog-
nostic factors with 95% CIs on the various outcomesseparately for the ATG-F group and the control group.
There were no strong interactions between treatment
and prognostic factors with all P values of tests of inter-
active effects ..05, except for aGVHD II to IV, indi-
cating that the effects of prognostic factors detected
equally apply to both treatment groups. The effect of
donor age on NRM was more pronounced in the
ATG-F group (HR 5 3.11; 95% CI, 1.25-7.73) than
in the control group (HR 5 1.01; 95% CI, 0.47-
2.15), test of interaction P5 .067, but it has to be con-
sidered that the 95%CIs of the HRs are large, and that
multiple comparisons are performed in these extended
subgroup analyses.Effects of HLA-Mismatch (4-Digit, 10/10) on
Outcome and Treatment Effect
To evaluate the influence of HLA-mismatch
(4-digit, 10/10) on outcome and on the treatment ef-
fect (ATG-F versus control), the effects of treatment
and the degree of HLA-mismatch on the various end-
points are shown in Table 3, Table 4, and Figure 2.
One hundred nineteen patients underwent transplan-
tation from a 10/10-matched donor (ATG-F,
n5 61; control, n5 58), and 60 patients from a donor
with a mismatch (ATG-F, n 5 31; control, n 5 29).
Table 3. Treatment Effect (ATG-F versus Control) (Multiple Regression Analyses, Adjusted for Disease Status, and Stem-Cell
Source)
Outcome
Treatment Effect ATG-F versus Control Test of Heterogeneous
Treatment Effects
(Interaction)HLA 10/10 4-Digit Match (N 5 119) HLA 10/10 4-Digit Mismatch (N 5 60)
HR 95% CI HR 95% CI P Value
aGVHD II-IV 0.48 0.27-0.86 0.61 0.26-1.44 .65
aGVHD III-IV 0.39 0.16-0.93 0.54 0.10-2.94 .73
cGVHD limited/extensive 0.22 0.11-0.45 0.58 0.27-1.24 .06
cGVHD extensive 0.08 0.03-0.28 0.32 0.12-0.86 .09
Relapse 1.45 0.69-3.03 1.43 0.63-3.27 .98
NRM 0.68 0.33-1.39 0.53 1.18-1.60 .71
DFS 0.98 0.59-1.62 0.99 0.52-1.88 .98
OS 0.88 0.51-1.50 0.87 0.44-1.71 .99
ATG-F indicates antithymocyte globulin Fresenius; HR, hazard ratio; CI, confidence interval; aGVHD, acute graft-versus-host disease; cGVHD, chronic
graft-versus-host disease; NRM, nonrelapse mortality; DFS, disease-free survival; OS, overall survival.
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tients with HLA-matched and HLA-mismatched do-
nors (ie, tests for interactions [Table 3]), showed
P values ..50, except for limited/extensive cGVHD
(P5 .06) and for extensive cGVHD (P5 .09). This in-
dicates that for the positive effect of ATG-F on
aGVHD and cGVHD shown in previous analyses
[9,23], no large differences are seen in patients with
10/10-matched donors and in patients with mis-
matched donors. The beneficial effect of ATG-F on
extensive cGVHD is somewhat stronger with HLA-
matched (HR 5 0.08; 95% CI, 0.03-0.28) than with
HLA-mismatched donors (HR 5 0.32; 95% CI,
0.12-0.86), but also present with this degree of mis-
match (Figure 2B). Also, for limited/extensive
cGVHD, the effect is stronger withHLA-matched do-
nors, but tends to result in the same direction for
HLA-mismatched donors (Table 3). No effect of
ATG-F versus control on relapse risk, NRM, DFS,
and OS was seen in HLA-matched as well as in
HLA-mismatched transplantations (Table 3).
Patients with a mismatched donor had a slightly
lower aGVHD III to IV rate than patients with a 10/Table 4. Effect of HLA-Mismatch (10/10, 4-Digit) (Multiple
Regression Analyses, Adjusted for Treatment, Disease Status,
and Stem-Cell Source)
Outcome
Effect of HLA 10/10 4-Digit Mismatch
Mismatch vs No Mismatch
HR 95% CI P Value
aGvHD II-IV 0.74 0.38-1.41 .36
aGvHD III-IV 0.39 0.13-1.16 .09
cGvHD limited/ extensive 1.27 0.68-2.38 .45
cGvHD extensive 1.18 0.58-2.39 .65
Relapse 1.74 0.77-3.94 .19
NRM 1.02 0.47-2.20 .96
DFS 1.30 0.75-2.26 .36
OS 1.30 0.72-2.33 .38
HR indicates hazard ratio; CI, confidence interval; aGVHD, acute
graft-versus-host disease; cGVHD, chronic graft-versus-host disease;
NRM, nonrelapse mortality; DFS, disease-free survival; OS, overall
survival.10-matched donor (Figure 2A), but as the analysis of
the effect of HLA 10/10 mismatch shows (Table 4),
this may still be due to chance (HR 5 0.39; 95% CI,
0.13-1.16; P 5 .09). With respect to aGVHD II to
IV, there is almost no difference between patients
with a 10/10 matched and mismatched donor
(HR 5 0.74; 95% CI, 0.38-1.41; P 5 .36; Table 4).
The cGVHD rates are also similar for patients with
10/10 matched and mismatched donors, and no
effect of HLA-mismatch on relapse, NRM, DFS,
and OS could be shown (Table 4).DISCUSSION
Within this prospective randomized trial, 3 im-
portant prognostic factors independently influencing
the outcome after HSCT from unrelated donors
could be identified: patient age, donor age, and dis-
ease status. Whereas older patient age and advanced
disease are known prognostic factors in allogeneic
HSCT from matched sibling donors, the influence
of older donor age on severe aGVHD and cGVHD,
as well as OS, has only be suggested from registry
data analysis [24].
Retrospective analysis on 6978 BM transplanta-
tions performed within the national marrow donor
program revealed donor age significantly related to
GVHD and OS with an OS rate of 33% and 25% in
recipients who underwent transplantations from do-
nors ages 18 to 30 and .45 years, respectively [24].
A recent registry analysis in 932 recipients of unrelated
donor blood-derived grafts showed a beneficial effect
of higher CD34 cell counts in the grafts [25]. This ret-
rospective patient cohort differs from our trial among
other aspects with regard to sample size, patient age,
including children, as well as the inclusion of ablative
and nonablative conditioning; in addition, any influ-
ence of patient and donor age was not reported [25].
A large, retrospective single-center analysis on risk
factors for aGVHD and cGVHD in 2941 patients who
Figure 2. Effect of treatment and HLA-mismatch. (A) Effect on acute graft-versus-host disease (aGVHD) III-IV. (B) Effect on extensive chronic graft-
versus-host disease (cGVHD). (C) Effect on relapse.
Biol Blood Marrow Transplant 18:1716-1726, 2012 1723Prognostic Factors in Allogeneic HSCTunderwent transplantations from related and unrelated
donors in Seattle demonstrated increased risks for
aGVHD and, to a lesser extent, for cGVHD by the
use of mismatched or matched unrelated donors.
Older patient age, female donors to male recipients,
and the use of G-CSF-mobilized PB cells were associ-ated with increased risks for cGVHD, whereas the use
of TBI was associated with increased risk for aGVHD,
suggesting different mechanisms in aGVHD and
cGVHD induction, respectively [17].
Because only 20% of the patients in our study re-
ceived BM transplantations, no extensive analysis
1724 Biol Blood Marrow Transplant 18:1716-1726, 2012J. Finke et al.regarding the influence of graft source can be per-
formed. Recently, analysis from the Blood andMarrow
Transplant Clinical Trials Network trial 0201, ran-
domly comparing BM with blood-derived grafts in
unrelated donor transplantations, showed an increased
risk of cGVHD without a negative influence on sur-
vival after blood-derived grafts [26]. In this trial, which
tested the influence of graft source, the majority of pa-
tients received a GVHD prophylaxis with calcineurin
inhibitors and methotrexate only. In contrast, our
GVHD prophylaxis trial tested the role of additional
ATG-F, demonstrating the effective reduction of the
risk of cGVHD [9,23]. With different questions
addressed in these 2 randomized trials, no direct
comparison can be made. However, because 80% of
the patients in our GVHD prevention trial received
blood-derived grafts, we suggest the additional use of
ATG-F to avoid severe aGVHD and cGVHD for
this population.
The negative effect of diagnosis of MDS and
CML, respectively, in our trial has to be interpreted
with caution, because few patients with these diagno-
ses and all with high risk underwent transplantations.
Several issues have to be kept in mind when inter-
preting our results and putting these into the general
context of unrelated HSCT. In our randomized trial,
only adult patients up to the age of 60 with a Karnofsky
performance score of at least 60 were included, and
they frequently had advanced and active malignant dis-
ease. Furthermore, 82% of the patients received
G-CSF-primed PB-derived grafts, and all our patients
received high-dose myeloablative conditioning.
Therefore, our analysis cannot address issues related
to immunosuppressive conditioning only, transplanta-
tions with reduced intensity conditioning, or severe
comorbidities.
Recently, a retrospective study fromNorthAmerica
focused on the influence of ATGor alemtuzumab in re-
lated and unrelated donor transplantation after reduced
intensity conditioning [27]. Because of higher relapse
rates, the authors suggested a cautious approach to
the general use of these agents. Of note, other types of
ATG, different from ATG-F applied in our trial, were
used in the American transplantation centers. Further-
more, the low-intensity conditioning in contrast to
high-dose myeloablative conditioning in our trial may
have contributed to the worse outcome.
When planning the trial in the early 2000s, com-
patibility with 2-digit typing for class I was generally
accepted and the role of HLA-C matching was less
clear. When communicating the beneficial effect of
additional ATG-F forGVHDprophylaxis on aGVHD
and cGVHD [9], the question was raised whether this
effect still holds true in 10/10 allele matched transplan-
tations.With our present analysis on 179 patients with
complete data on 4-digit typing of 201 study patients,
no interactive effects between matching and treatmentcould be demonstrated. This indicates that for the pos-
itive effect of ATG-F on aGVHD and cGVHD shown
in previous analyses [9], no large differences are seen in
patients with 10/10-matched donors and in patients
with mismatched donors.
We did not find a significant influence of 10/10
mismatching on outcome in our trial. The results
were similar when we looked at the influence of
HLA-C mismatch in otherwise 8/8-matched patient/
donor pairs (results not shown in detail). It has to be
stressed that this does not mean that allele matching
is of minor importance. All patients were required to
be matched on the allele 4-digit level in DRB1 and
DQB1. In light of new analyses from large patient
cohorts, the role of DQB1 can be questioned. The
value of HLA-matching has been established from
large registries. Our trial with 201 patients is too small
to draw definite conclusions regarding the value of spe-
cific mismatches. However, even in 10/10 HLA-
matched unrelated donor transplantations, the inci-
dence of severe aGVHD and cGVHD was not trivial
and the addition of ATG-F can reduce this risk. Mis-
matches in unrelated donor transplantations are more
often accepted in patients with younger age and/or
more advanced disease [4]. The use of ATG-F can re-
duce the risk of GVHD both in completely matched
as well as mismatched transplantations, similar to the
degree of mismatching that was seen in our trial.
Our data are of relevance for strategies in unrelated
donor HSCT. Patient-related and disease-related fac-
tors often cannot be influenced: patient age has to be
accepted and remission frequently cannot be achieved
in high-risk or advanced leukemia; in fact, extensive
therapy before allogeneic HSCT is an independent
risk factor for OS after HSCT [19]. Novel approaches
apply ablative or reduced intensity conditioning in
aplasia after antileukemic chemotherapy and result in
promising outcomes [28-30].
In contrast, donor and transplantation-related is-
sues can be adapted to the need of the patient (eg, for
patients with high-risk malignant disease, a rapid
donor search is warranted). A prospective trial in
high-risk patients with AML demonstrated the benefi-
cial effect of allogeneic HSCT as compared to no
HSCT on OS, with grafts derived from unrelated do-
nors (HR 5 0.69; 95% CI, 0.48-0.99; P 5 .046) [31].
By choosing a younger unrelated donor, severe
aGVHD and cGVHD, as well as OS after unrelated
donor HSCT, can be significantly improved.ATG-FRESENIUS TRIAL GROUP
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